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Background
The recent Combi-v [1] and Combi-d [2,3], phase III
randomized trials, showed, respectively, an OS benefit
with Dabrafenib/Trametinib combination versus Vemur-
afenib and an improvement in PFS and ORR with the
same combination versus Dabrafenib alone, in BRAF
V600E/K mutation positive metastatic or unresectable
cutaneous melanoma. We report the case of a young
patient with metastatic melanoma treated with anti-
BRAF/antiMEK combination.
Case report
A 36-years woman referred to our institution in March
2014, after the diagnosis of metastatic melanoma. ECOG
Performance Status was 1. No comorbidities, no previous
melanoma treatment. In May 2011 the patient reported a
traumatic event which resulted in the removal of a mole
localized in the right thigh. Since August 2013 she noted a
swelling in the right area of the groin. It increased con-
stantly causing pain, deambulation problems and limiting
daily activities. On January 2014, due to the worsening of
the swelling and pain, which resulted in the patient
becoming unable to maintain a sitting position, she under-
went an ultrasound exam that displayed pathological
lymph nodes. A FNAB showed a metastatic localization of
melanoma, S 100+++, Hbm 45++. BRAFV600E mutation
was detected with Cobas 4800 BRAF mutation test. A CT/
PET displayed conglobated pathological lymph nodes in
right groin of around 10 cm; right iliac obturator lymph
node of 6 cm and osteolytic lesion at sacroiliac articula-
tion. In April 2014, after adequate screening, the patient
began Dabrafenib/Trametinib combination under the
Compassionate Use program. Just after one month of
treatment she reported clinical benefit in terms of deam-
bulation improvement and pain relief. During the second
month of therapy the treatment with Dabrafenib was with-
drawn for some days, due to two episodes of hyperpyrexia
up to 39°C, treated with Paracetamol. Progressively the
antiBRAF drug was reintroduced with no further interrup-
tion. The CT/PET performed after three and six month of
treatment showed a good response to the therapy with a
dimensional decrease and SUV reduction of more than
50% in all target lesions. Currently the patient is continu-
ing the treatment; her ECOG PS is 0. She does not require
any antalgic drugs. Our aim is obtain the maximum reduc-
tion to allow a surgical approach.
Conclusion
In our case the Dabrafenib/Trametinib (antiBRAF/anti-
MEK) combination leads to a fast clinical and radiologi-
cal disease response with a good toxicity profile and a
good management of AEs.
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